| Oct 29 |
Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook
|
| Oct 29 |
Novartis Lifts Guidance Again After Key Drugs Help Results
|
| Oct 29 |
Novartis says more time needed for cancer therapy added with MorphoSys deal
|
| Oct 29 |
Novartis Posts Results Above Estimates, Raises Outlook
|
| Oct 29 |
Trending tickers: Alphabet, Ford, PayPal, AMD and Trump Media
|
| Oct 29 |
Biogen refreshes its C-suite; Novartis writes down MorphoSys assets
|
| Oct 29 |
Novartis: Q3 Earnings Snapshot
|
| Oct 29 |
The Zacks Analyst Blog Novartis, Reddit and Check Point Software Technologies
|
| Oct 29 |
Novartis Q3 Non-GAAP EPS of $2.06, revenue of $12.83B
|
| Oct 29 |
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
|
